← Back to Search

Bronchodilator

Bronchodilators for Chronic Obstructive Pulmonary Disease (Glittre Trial)

N/A
Waitlist Available
Led By Didier Saey, Ph.D.
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 days between the cardiopulmonary maximal exercise test on the bike and the first 1-minute stst, and up to 13 days between the test on the bike and the 2nd 1-minute stst
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions

Summary

This project is aimed to assess the responsiveness of the Glittre ADL-test and the 1-Minute Sit-to-Stand test (1-Minute STST) to acute bronchodilation in patients with COPD. We also aim to investigate the physiological and perceptual response to bronchodilation of the Glittre ADL-test and the 1-minute STST. The specific objectives are 1)To measure the changes in time for completion of the Glittre ADL-test and the number of standing up during the 1-minute STST induced by a single dose of nebulized ipratropium bromide/salbutamol sulfate against those induced by a placebo in patients with moderate to severe COPD and 2)To compare in patients with moderate to severe COPD the CR (minute ventilation (VE), oxygen uptake (VO2), carbon dioxide production (VCO2) and heart rate) and symptomatic (dyspnea and leg fatigue perception) responses during the Glittre ADL-test and the 1-Minute STST following a single dose of ipratropium bromide/salbutamol sulfate or placebo. We suppose among others that the Glittre test completion time will be lesser, that the number of repetitions in the 1-Minute STST will be higher and symptoms intensity will be lesser among patients with COPD receiving bronchodilators.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 days between the cardiopulmonary maximal exercise test on the bike and the first 1-minute stst, and up to 13 days between the test on the bike and the 2nd 1-minute stst
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 days between the cardiopulmonary maximal exercise test on the bike and the first 1-minute stst, and up to 13 days between the test on the bike and the 2nd 1-minute stst for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glittre ADL-test time completion
Secondary study objectives
Accelerometry
Accelerometry-steps
Accelerometry-subduration
+9 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BronchodilatorsExperimental Treatment2 Interventions
Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
Group II: PlaceboPlacebo Group2 Interventions
Nebulization of a placebo before the administration of the Glittre ADL-test
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebos
2019
Completed Phase 4
~2030

Find a Location

Who is running the clinical trial?

Institut Universitaire de Cardiologie et Pneumologie de QuébecUNKNOWN
Laval UniversityLead Sponsor
430 Previous Clinical Trials
178,361 Total Patients Enrolled
Institut universitaire de cardiologie et de pneumologie de Québec, University LavalOTHER
22 Previous Clinical Trials
4,209 Total Patients Enrolled
~4 spots leftby Nov 2025